Here's Why Emergent Biosolutions Dropped as Much as 11.8% Today

Markets Motley Fool

What happened

Continue Reading Below

Shares of public health threat neutralizer Emergent Biosolutions (NYSE: EBS) fell nearly 12% today for, well, no compelling reason at this time. Sometimes stocks go up, and sometimes they go down. But it's important to remember that single-day movements have little effect on the long-term performance of a company. 

So what

If you really wanted to reach, then there is some news in the company's field. Researchers at the University of Nebraska-Lincoln reported that an experimental flu vaccine could provide lifetime immunity to influenza strains. In other words, a universal flu shot.

Except, of course, the results were only reported in a study concerning mice, which means it's far too early to assume the universal flu vaccine would work in humans. Many scientists have been hunting for such a treatment for decades.

It's also extremely unlikely to have an effect on Emergent Biosolutions, which only has flu vaccines in its pipeline at the moment. Through the first nine months of this year, nearly 70% of its product revenue was generated from its anthrax product, which is mostly sold to the U.S. government. 

Continue Reading Below

Shareholders certainly never want to see their holdings decrease by double digits, but this seems relatively innocent. Emergent Biosolutions stock is up 47% -- after factoring in today's drop -- in the last year alone. So this may just be a large shareholder taking some gains before the end of the year.

Now what

Unfortunately, this appears to be a simple case of "sometimes stocks go down for no good reason." There's no reason to alter your long-term investment thesis about a company for a single-day movement that isn't supported by actionable news. 

10 stocks we like better than Emergent BioSolutions
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Emergent BioSolutions wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 6, 2017

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.